Grace Therapeutics announced that results from its STRIVE-ON Phase 3 trial of GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH), will be presented at AAN 2026. The trial showed a 19% reduction in clinically significant hypotension episodes with GTx-104 compared to oral nimodipine, along with better dosing consistency and improved functional outcomes at 90 days. Safety profiles were comparable between treatments, with no new safety concerns. These results support GTx-104 as a promising IV treatment option for aSAH, potentially improving patient management and outcomes.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
